申请人:National Science Council
公开号:US05646164A1
公开(公告)日:1997-07-08
The present inventors have discovered three classes of novel .alpha.-methylene-.gamma.-butyrolactones with excellent antiplatelet activity. As a result of intensive studies, it has been found that compounds represented by the formula I-III are potent inhibitors of platelet aggregation. ##STR1## For the formula I, R.sub.1 is a methyl, a phenyl group optionally substituted with one or two group selected from halide, (C.sub.1 -C.sub.4) alkyl, (C.sub.1 -C.sub.4) alkoxy, phenyl, nitro, amino. For the formula II, R.sub.1 is a methyl, a phenyl group optionally substituted with one or two group selected from halide, (C.sub.1 -C.sub.4) alkyl, (C.sub.1 -C.sub.4) alkoxy, phenyl, nitro, amino; R.sub.2 represents hydrogen, halide, (C.sub.1 -C.sub.4) alkyl, phenyl, nitro, amino; R.sub.3 represents hydrogen, halide, (C.sub.1 -C.sub.4) alkyl, phenyl, nitro, amino. For the formula III, R.sub.1 is a methyl, a phenyl group optionally substituted with one or two group selected from halide, (C.sub.1 -C.sub.4) alkyl, (C.sub.1 -C.sub.4) alkoxy, phenyl, nitro, amino; R.sub.4 represents hydrogen, hydroxy, (C.sub.1 -C.sub.4) alkyl. The present invention also provides a cost-efficient method for the preparation of formula I-III. Formula I-III may be administered orally or parenterly with an inert diluent or with a pharmaceutically acceptable carrier in the treatment or the prevention of cardiovascular disease.
目前的发明者发现了三类具有出色抗血小板活性的新型α-亚甲基-γ-丁酸内酯。经过深入研究发现,由I-III式表示的化合物是有效的血小板聚集抑制剂。对于式I,R.sub.1是一个甲基,一个苯基,可选择地取代为卤素、(C.sub.1 -C.sub.4)烷基、(C.sub.1 -C.sub.4)氧烷基、苯基、硝基、氨基中的一个或两个基团。对于式II,R.sub.1是一个甲基,一个苯基,可选择地取代为卤素、(C.sub.1 -C.sub.4)烷基、(C.sub.1 -C.sub.4)氧烷基、苯基、硝基、氨基中的一个或两个基团;R.sub.2代表氢、卤素、(C.sub.1 -C.sub.4)烷基、苯基、硝基、氨基;R.sub.3代表氢、卤素、(C.sub.1 -C.sub.4)烷基、苯基、硝基、氨基。对于式III,R.sub.1是一个甲基,一个苯基,可选择地取代为卤素、(C.sub.1 -C.sub.4)烷基、(C.sub.1 -C.sub.4)氧烷基、苯基、硝基、氨基中的一个或两个基团;R.sub.4代表氢、羟基、(C.sub.1 -C.sub.4)烷基。本发明还提供了一种成本效益高的制备I-III式的方法。I-III式可以通过口服或肌注与惰性稀释剂或药用载体一起使用,用于治疗或预防心血管疾病。